Controlled release of biologics for the treatment of type 2 diabetes

Journal of Controlled Release

Volumn 240, Issue , 2016, Pages 151-164

  Gilroy, Caslin A ^a   Luginbuhl, Kelli M ^a   Chilkoti, Ashutosh ^a  

^a Duke University   (United States)

Author keywords

Controlled release; Diabetes; Drug delivery; GLP 1; Insulin; Peptide

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG DELIVERY; INSULIN; MEDICAL PROBLEMS; PATIENT TREATMENT; PEPTIDES;

CONTROLLED RELEASE; DRUG DELIVERY STRATEGIES; GLP-1; GLUCAGON-LIKE PEPTIDE-1; HEALTH-CARE SYSTEM; INHERENT INSTABILITY; PATIENT COMPLIANCE; STRUCTURAL MODIFICATIONS;

DISEASES;

ALBIGLUTIDE; ALBUMIN; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; LIXISENATIDE; POLYMER; PROTEINASE; RECOMBINANT HUMAN INSULIN; SEMAGLUTIDE; TASPOGLUTIDE; ANTIDIABETIC AGENT; BIOLOGICAL PRODUCT; INSULIN;

CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SPECIFICITY; HUMAN; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL CLEARANCE; REVIEW; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; PROCEDURES; TREATMENT OUTCOME;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL PRODUCTS; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; TREATMENT OUTCOME;

EID: 84949658050     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.12.002     Document Type: Review

References (161)

1. [1] Centers for Disease Control and Prevention, US Department of Health and Human Services, (eds.) National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014, 2014 (Atlanta).
2. [2] American Diabetes Association Position Statement, Standards of medical care in diabetes — 2015. Diabetes Care, 38, 2015, S4.
3. [3] International Expert Committee, International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32 (2009), 1327–1334.
4. [4] Handelsman, Y., Bloomgarden, Z.T., Grunberger, G., Umpierrez, G., Zimmerman, R.S., Bailey, T.S., Blonde, L., Bray, G.A., Cohen, A.J., Dagogo-Jack, S., American Association of Clinical Endocrinologists and American College of Endocrinology — clinical practice guidelines for developing a diabetes mellitus comprehensive care plan — 2015. Endocr. Pract. 21 (2015), 1–87.
5. [5] Bailey, C.J., The current drug treatment landscape for diabetes and perspectives for the future. Clin. Pharmacol. Ther. 98 (2015), 170–184.
6. [6] Bliss, M., The Discovery of Insulin. 2007, University of Chicago Press, Chicago.
7. [7] Felig, P., Protamine insulin: Hagedorn's pioneering contribution to drug delivery in the management of diabetes. J. Am. Med. Assoc. 251 (1984), 393–396.
8. [8] Greene, J.A., Riggs, K.R., Why is there no generic insulin? Historical origins of a modern problem. N. Engl. J. Med. 372 (2015), 1171–1175.
9. [9] Goeddel, D.V., Kleid, D.G., Bolivar, F., Heyneker, H.L., Yansura, D.G., Crea, R., Hirose, T., Kraszewski, A., Itakura, K., Riggs, A.D., Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc. Natl. Acad. Sci. U. S. A. 76 (1979), 106–110.
10. [10] DeWitt, D.E., Hirsch, I.B., Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. J. Am. Med. Assoc. 289 (2003), 2254–2264.
11. [11] Heinemann, L., Linkeschova, R., Rave, K., Hompesch, B., Sedlak, M., Heise, T., Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23 (2000), 644–649.
12. [12] National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, (eds.) Types of Insulin, 2013, National Diabetes Information Clearinghouse, Bethesda.
13. [13] U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Toujeo Solostar NDA 206538 Approval Label. February 25, 2015 (in).
14. [14] U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Levemir NDA 021536 Approval Label. February 25, 2015 (in).
15. [15] U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Insulin Degludec and Insulin Degludec/Insulin Aspart Treatment to Improve Glycemic Control in Patients with Diabetes Mellitus NDAs 203314 and 203313 Briefing Document, in, 2012.
16. [16] Blundell, T., Dodson, G., Hodgkin, D., Mercola, D., Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv. Protein Chem. 26 (1972), 279–402.
17. [17] Owens, D.R., Zinman, B., Bolli, G.B., Insulins today and beyond. Lancet 358 (2001), 739–746.
18. [18] Hirsch, I.B., Insulin analogues. N. Engl. J. Med. 352 (2005), 174–183.
19. [19] Howey, D.C., Bowsher, R.R., Brunelle, R.L., Woodworth, J.R., [Lys(B28), pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43 (1994), 396–402.
20. [20] Berenson, D.F., Weiss, A.R., Wan, Z.-l., Weiss, M.A., Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering. Ann. N. Y. Acad. Sci. 1243 (2011), E40–E54.
21. [21] Becker, R.H., Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol. Ther. 9 (2007), 109–121.
22. [22] Home, P.D., Barriocanal, L., Lindholm, A., Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur. J. Clin. Pharmacol. 55 (1999), 199–203.
23. [23] Rahuel-Clermont, S., French, C.A., Kaarsholm, N.C., Dunn, M.F., Chou, C.I., Mechanisms of stabilization of the insulin hexamer through allosteric ligand interactions. Biochemistry 36 (1997), 5837–5845.
24. [24] Morrow, L., Muchmore, D.B., Hompesch, M., Ludington, E.A., Vaughn, D.E., Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabetes Care 36 (2013), 273–275.
25. [25] Rassam, A.G., Zeise, T.M., Burge, M.R., Schade, D.S., Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. Diabetes Care 22 (1999), 133–136.
26. [26] Novo Nordisk A/S, Novo Nordisk Completes Phase 3a Trials Comparing Faster-Acting Insulin Aspart with NovoRapid® in People with Type 1 and Type 2 Diabetes. [Press release], in, 2015.
27. [27] H.B. Olsen, S. Havelund, U. Ribel, J. Sturis, H. Naver, M. Schlein, S. Ludvigsen, Preparation comprising insulin, nicotinamide and an amino acid, in, Google Patents, 2010.
28. [28] Sorli, C., New developments in insulin therapy for type 2 diabetes. Am. J. Med. 127 (2014), S39–S48.
29. [29] Halozyme Therapeutics, NCT01194258. Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus, in, 2010, (Updated last August 1, 2014).
30. [30] Rosenstock, J., Schwartz, S.L., Clark, C.M., Park, G.D., Donley, D.W., Edwards, M.B., Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001), 631–636.
31. [31] Rosenstock, J., Dailey, G., Massi-Benedetti, M., Fritsche, A., Lin, Z., Salzman, A., Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28 (2005), 950–955.
32. [32] Shiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., Becker, R.H.A., Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes. Metab. 17 (2015), 254–260.
33. [33] Bolli, G.B., Riddle, M.C., Bergenstal, R.M., Ziemen, M., Sestakauskas, K., Goyeau, H., Home, P.D., E.s.i. on behalf of the, New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes. Metab. 17 (2015), 386–394.
34. [34] Whittingham, J.L., Havelund, S., Jonassen, I., Crystal structure of a prolonged-acting insulin with albumin-binding properties. Biochemistry 36 (1997), 2826–2831.
35. [35] Havelund, S., Plum, A., Ribel, U., Jonassen, I., Volund, A., Markussen, J., Kurtzhals, P., The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res. 21 (2004), 1498–1504.
36. [36] Heinemann, L., Sinha, K., Weyer, C., Loftager, M., Hirschberger, S., Heise, T., Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet. Med. 16 (1999), 332–338.
37. [37] Kolendorf, K., Ross, G.P., Pavlic-Renar, I., Perriello, G., Philotheou, A., Jendle, J., Gall, M.A., Heller, S.R., Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet. Med. 23 (2006), 729–735.
38. [38] Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 29 (2006), 1269–1274.
39. [39] Novo Nordisk A/S, Novo Nordisk Receives US FDA Approval for Tresiba® and Ryzodeg® 70/30. in, 2015.
40. [40] Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D., Wahlund, P.-O., Ribel, U., Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29 (2012), 2104–2114.
41. [41] Hompesch, M., Morrow, L., Watkins, E., Roepstorff, C., Thomsen, H.F., Haahr, H., Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus. Clin. Ther. 36 (2014), 507–515.
42. [42] Ratner, R.E., Gough, S.C.L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., Zinman, B., Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes. Metab. 15 (2013), 175–184.
43. [43] Dżygało, K., Golicki, D., Kowalska, A., Szypowska, A., The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials. Acta Diabetol. 52 (2015), 231–238.
44. [44] Sinha, V.P., Choi, S.L., Soon, D.K.W., Mace, K.F., Yeo, K.P., Lim, S.T.H., Howey, D.C., Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J. Clin. Pharmacol. 54 (2014), 792–799.
45. [45] Bergenstal, R.M., Rosenstock, J., Arakaki, R.F., Prince, M.J., Qu, Y., Sinha, V.P., Howey, D.C., Jacober, S.J., A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin–treated patients with type 2 diabetes. Diabetes Care 35 (2012), 2140–2147.
46. [46] Moore, M.C., Smith, M.S., Sinha, V.P., Beals, J.M., Michael, M.D., Jacober, S.J., Cherrington, A.D., Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 63 (2014), 494–504.
47. [47] Eli Lilly and Company, Lilly Announces Update on Regulatory Submission Timing for Basal Insulin Peglispro. [Press Release], in, 2015.
48. [48] Rave, K., Potocka, E., Boss, A.H., Marino, M., Costello, D., Chen, R., Pharmacokinetics and linear exposure of AFRESA™ compared with the subcutaneous injection of regular human insulin. Diabetes Obes. Metab. 11 (2009), 715–720.
49. [49] Pfützner, A., Forst, T., Pulmonary insulin delivery by means of the technosphere™ drug carrier mechanism. Expert Opin. Drug Deliv. 2 (2005), 1097–1106.
50. [50] Heinemann, L., Traut, T., Heise, T., Time-action profile of inhaled insulin. Diabet. Med. 14 (1997), 63–72.
51. [51] Heinemann, L., Jacques, Y., Oral insulin and buccal insulin: a critical reappraisal. J. Diabetes Sci. Technol. 3 (2009), 568–584.
52. [52] Bernstein, G., Delivery of insulin to the buccal mucosa utilizing the RapidMist™ system. Expert Opin. Drug Deliv. 5 (2008), 1047–1055.
53. [53] Cernea, S., Kidron, M., Wohlgelernter, J., Modi, P., Raz, I., Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin. Ther. 26 (2004), 2084–2091.
54. [54] Generex Biotechnology Corporation, Generex Oral-lyn™ Results in More Rapid Reductions of HbA1c in Shreya's Phase III Study of Type 2 Diabetes in India. [Press Release], in, 2013.
55. [55] Generex Biotechnology Corporation, Generex Provides Update on Buccal Insulin Formulation Enhancement Project. [Press Release], in, 2015.
56. [56] Modi, P., Mihic, M., Lewin, A., The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist™ system. Diabetes Metab. Res. Rev. 18 (2002), S38–S42.
57. [57] Generex Biotechnology Corporation, Generex Provides Update on Success of Buccal Insulin Formulation Enhancement Project. in, 2015.
58. [58] Pridgen, E.M., Alexis, F., Kuo, T.T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R.S., Langer, R., Farokhzad, O.C., Transepithelial transport of Fc -targeted nanoparticles by the neonatal Fc receptor for oral delivery. Sci. Transl. Med., 5, 2013, 213ra167.
59. [59] Sharma, G., Sharma, A.R., Nam, J.-S., Doss, G.P.C., Lee, S.-S., Chakraborty, C., Nanoparticle based insulin delivery system: the next generation efficient therapy for type 1 diabetes. J. Nanobiotechnol., 13, 2015, 74.
60. [60] Jin, Y., Song, Y., Zhu, X., Zhou, D., Chen, C., Zhang, Z., Huang, Y., Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33 (2012), 1573–1582.
61. [61] Novo Nordisk A/S, NCT02470039. Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy, in, 2015, (Updated last October 14, 2015).
62. [62] Maher, S., Leonard, T.W., Jacobsen, J., Brayden, D.J., Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 61 (2009), 1427–1449.
63. [63] Tomita, M., Hayashi, M., Awazu, S., Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in caco-2 cells. J. Pharm. Sci. 85 (1996), 608–611.
64. [64] Aungst, B.J., Absorption enhancers: applications and advances. AAPS J. 14 (2012), 10–18.
65. [65] Oramed Pharmaceuticals Inc., Oramed Completes Randomization of over 50% of Patients in Phase IIb Oral Insulin Study. in, 2015.
66. [66] Oramed Pharmaceuticals Inc., Oramed Pharmaceuticals Presents Data from Phase IIa Trial with ORMD-0801 in Type 2 Diabetes at the 2014 Diabetes Summit. [Press Release], in, 2014.
67. [67] M. Kidron, Methods and Compositions for Oral Administration of Proteins, in, Google Patents, 2007.
68. [68] Chou, D.H.-C., Webber, M.J., Tang, B.C., Lin, A.B., Thapa, L.S., Deng, D., Truong, J.V., Cortinas, A.B., Langer, R., Anderson, D.G., Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 2401–2406.
69. [69] Yu, J., Zhang, Y., Ye, Y., DiSanto, R., Sun, W., Ranson, D., Ligler, F.S., Buse, J.B., Gu, Z., Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc. Natl. Acad. Sci. U. S. A., 2015.
70. [70] Di, J., Price, J., Gu, X., Jiang, X., Jing, Y., Gu, Z., Ultrasound-triggered regulation of blood glucose levels using injectable nano-network. Adv. Healthc. Mater. 3 (2014), 811–816.
71. [71] Merck & Co., Merck to Acquire SmartCells, Inc. [Press Release], in, 2010.
72. [72] Hurley, D., Why Are So Few Blockbuster Drugs Invented Today?. The New York Times Magazine, 2014, Arthur Ochs Sulzberger, New York City, New York.
73. [73] T.M. Lancaster, S. Murikipudi, T.C. Zion, Uses of macrophage mannose receptor to screen compounds and uses of these compounds, in, Google Patents, 2012.
74. [74] Merck Sharp & Dohme Corp., NCT02269735. A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001), in, 2014, (Updated last November 1, 2015).
75. [75] U.S. Food and Drug Administration, Center for Devices and Radiological Health, Dexcom G4 PLATINUM Continuous Glucose Monitoring System — P120005/S018, in, 2014.
76. [76] Christiansen, M., Bailey, T., Watkins, E., Liljenquist, D., Price, D., Nakamura, K., Boock, R., Peyser, T., A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technol. Ther. 15 (2013), 881–888.
77. [77] Rebrin, K., Steil, G.M., van Antwerp, W.P., Mastrototaro, J.J., Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am. J. Physiol. Endocrinol. Metab. 277 (1999), E561–E571.
78. [78] Sharkawy, A.A., Klitzman, B., Truskey, G.A., Reichert, W.M., Engineering the tissue which encapsulates subcutaneous implants. I. Diffusion properties. J. Biomed. Mater. Res. 37 (1997), 401–412.
79. [79] Dungel, P., Long, N., Yu, B., Moussy, Y., Moussy, F., Study of the effects of tissue reactions on the function of implanted glucose sensors. J. Biomed. Mater. Res. A 85A (2008), 699–706.
80. [80] Novak, M.T., Yuan, F., Reichert, W.M., Modeling the relative impact of capsular tissue effects on implanted glucose sensor time lag and signal attenuation. Anal. Bioanal. Chem. 398 (2010), 1695–1705.
81. [81] Heinemann, L., Krinelke, L., Insulin infusion set: the achilles heel of continuous subcutaneous insulin infusion. J. Diabetes Sci. Technol. 6 (2012), 954–964.
82. [82] U.S. Food and Drug Administration, Center for Devices and Radiological Health, BD FlowSmart Set 510(k) Premarket Notification, in, 2015.
83. [83] Kovatchev, B.P., Renard, E., Cobelli, C., Zisser, H.C., Keith-Hynes, P., Anderson, S.M., Brown, S.A., Chernavvsky, D.R., Breton, M.D., Farret, A., Pelletier, M.-J., Place, J., Bruttomesso, D., Del Favero, S., Visentin, R., Filippi, A., Scotton, R., Avogaro, A., Doyle, F.J., Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care 36 (2013), 1851–1858.
84. [84] Letourneau, R., Global Insulin Market Expected to Reach $32B by 2018. 2012, Healthcare Finance, HIMSS Media.
85. [85] Engelberg, A.B., Kesselheim, A.S., Avorn, J., Balancing innovation, access, and profits — market exclusivity for biologics. N. Engl. J. Med. 361 (2009), 1917–1919.
86. [86] Heinemann, L., Biosimilar insulins: how will this story evolve?. Diabetes Technol. Ther. 14 (2012), 986–988.
87. [87] Merck & Co., Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes. [Press Release], in, 2014.
88. [88] Bell, G.I., Santerre, R.F., Mullenbach, G.T., Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302 (1983), 716–718.
89. [89] Kreymann, B., Williams, G., Ghatei, M.A., Bloom, S.R., Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 2 (1987), 1300–1304.
90. [90] Holst, J.J., Glucagon-like peptide-1: from extract to agent. The claude bernard lecture. Diabetologia 49:2006 (2005), 253–260.
91. [91] Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007), 2131–2157.
92. [92] Hoffmann-La Roche, NCT02205528. A Study of Once-Daily RO6811135 in Participants With Type 2 Diabetes (T2D) Inadequately Controlled With Metformin, in, 2014, (Updated last December 1, 2015).
93. [93] Sadry, S.A., Drucker, D.J., Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9 (2013), 425–433.
94. [94] Fosgerau, K., Hoffmann, T., Peptide therapeutics: current status and future directions. Drug Discov. Today 20 (2015), 122–128.
95. [95] U.S. Food and Drug Administration, Approval Labels, in, 2005–2014.
96. [96] Vilsboll, T., Agerso, H., Krarup, T., Holst, J.J., Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 88 (2003), 220–224.
97. [97] Deacon, C.F., Johnsen, A.H., Holst, J.J., Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80 (1995), 952–957.
98. [98] de Meester, I., Lambeir, A.M., Proost, P., Scharpe, S., Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. Adv. Exp. Med. Biol. 524 (2003), 3–17.
99. [99] Deacon, C.F., Nauck, M.A., Toftnielsen, M., Pridal, L., Willms, B., Holst, J.J., Both subcutaneously and intravenously administered glucagon-like peptide-I are rapidly degraded from the Nh2-terminus in type-Ii diabetic-patients and in healthy-subjects. Diabetes 44 (1995), 1126–1131.
100. [100] Thornton, K., Gorenstein, D.G., Structure of glucagon-like peptide (7–36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. Biochemistry 33 (1994), 3532–3539.
101. [101] Adelhorst, K., Hedegaard, B.B., Knudsen, L.B., Kirk, O., Structure-activity studies of glucagon-like peptide-1. J. Biol. Chem. 269 (1994), 6275–6278.
102. [102] Gallwitz, B., Witt, M., Paetzold, G., Morys-Wortmann, C., Zimmermann, B., Eckart, K., Folsch, U.R., Schmidt, W.E., Structure/activity characterization of glucagon-like peptide-1. Eur. J. Biochem. 225 (1994), 1151–1156.
103. [103] Deacon, C.F., Knudsen, L.B., Madsen, K., Wiberg, F.C., Jacobsen, O., Holst, J.J., Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41 (1998), 271–278.
104. [104] Burcelin, R., Dolci, W., Thorens, B., Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metab. Clin. Exp. 48 (1999), 252–258.
105. [105] Siegel, E.G., Gallwitz, B., Scharf, G., Mentlein, R., Morys-Wortmann, C., Folsch, U.R., Schrezenmeir, J., Drescher, K., Schmidt, W.E., Biological activity of GLP-1-analogues with N-terminal modifications. Regul. Pept. 79 (1999), 93–102.
106. [106] Gallwitz, B., Ropeter, T., Morys-Wortmann, C., Mentlein, R., Siegel, E.G., Schmidt, W.E., GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro. Regul. Pept. 86 (2000), 103–111.
107. [107] Siegel, E.G., Scharf, G., Gallwitz, B., Mentlein, R., Morys-Wortmann, C., Folsch, U.R., Schmidt, W.E., Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. Eur. J. Clin. Investig. 29 (1999), 610–614.
108. [108] O'Harte, F.P., Mooney, M.H., Kelly, C.M., McKillop, A.M., Flatt, P.R., Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7–36)amide in obese diabetic ob/ob mice. Regul. Pept. 96 (2001), 95–104.
109. [109] Green, B.D., Mooney, M.H., Gault, V.A., Irwin, N., Bailey, C.J., Harriott, P., Greer, B., O'Harte, F.P., Flatt, P.R., N-terminal His(7)-modification of glucagon-like peptide-1(7–36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J. Endocrinol. 180 (2004), 379–388.
110. [110] Green, B.D., Gault, V.A., O'Harte, F.P., Flatt, P.R., Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr. Pharm. Des. 10 (2004), 3651–3662.
111. [111] Li, Y., Zheng, X., Tang, L., Xu, W., Gong, M., GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1. Peptides 32 (2011), 1303–1312.
112. [112] Sebokova, E., Christ, A.D., Wang, H.Y., Sewing, S., Dong, J.Z., Taylor, J., Cawthorne, M.A., Culler, M.D., Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency. Endocrinology 151 (2010), 2474–2482.
113. [113] Rosenstock, J., Balas, B., Charbonnel, B., Bolli, G.B., Boldrin, M., Ratner, R., Balena, R., Grp, T.-E.S., The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes the T-emerge 2 trial. Diabetes Care 36 (2013), 498–504.
114. [114] Goke, R., Fehmann, H.C., Linn, T., Schmidt, H., Krause, M., Eng, J., Goke, B., Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 268 (1993), 19650–19655.
115. [115] Barnett, A.H., Burger, J., Johns, D., Brodows, R., Kendall, D.M., Roberts, A., Trautmann, M.E., Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin. Ther. 29 (2007), 2333–2348.
116. [116] Bolli, G.B., Owens, D.R., Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. Diabetes Obes. Metab. 16 (2014), 588–601.
117. [117] Sanofi, Sanofi Provides Update on Lixisenatide New Drug Application in U.S. in, 2013.
118. [118] Sanofi, Sanofi New Drug Application for Lixisenatide Accepted For Review By FDA. in, 2015.
119. [119] Petrie, J.R., The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc. Diabetol., 12, 2013, 130.
120. [120] Kratz, F., Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132 (2008), 171–183.
121. [121] Bush, M.A., Matthews, J.E., De Boever, E.H., Dobbins, R.L., Hodge, R.J., Walker, S.E., Holland, M.C., Gutierrez, M., Stewart, M.W., Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes. Metabol. 11 (2009), 498–505.
122. [122] Matthews, J.E., Stewart, M.W., De Boever, E.H., Dobbins, R.L., Hodge, R.J., Walker, S.E., Holland, M.C., Bush, M.A., Albiglutide Study, G., Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 93 (2008), 4810–4817.
123. [123] Ahren, B., Johnson, S.L., Stewart, M., Cirkel, D.T., Yang, F., Perry, C., Feinglos, M.N., Group, H.S., HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 37 (2014), 2141–2148.
124. [124] Home, P.D., Shamanna, P., Stewart, M., Yang, F., Miller, M., Perry, C., Carr, M.C., Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes. Metab. 17 (2015), 179–187.
125. [125] Blair, H.A., Keating, G.M., Albiglutide: a review of its use in patients with type 2 diabetes mellitus. Drugs 75 (2015), 651–663.
126. [126] Trujillo, J.M., Nuffer, W., Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann. Pharmacother. 48 (2014), 1494–1501.
127. [127] Baggio, L.L., Huang, Q., Brown, T.J., Drucker, D.J., A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53 (2004), 2492–2500.
128. [128] Sisley, S., Gutierrez-Aguilar, R., Scott, M., D'Alessio, D.A., Sandoval, D.A., Seeley, R.J., Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J. Clin. Investig. 124 (2014), 2456–2463.
129. [129] Meece, J., Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog. Pharmacotherapy 29 (2009), 33S–42S.
130. [130] Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P.A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P.M., Zdravkovic, M., Bode, B., Group, L.-S., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009), 473–481.
131. [131] Lau, J., Bloch, P., Schaffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L.B., McGuire, J., Steensgaard, D.B., Strauss, H.M., Gram, D.X., Knudsen, S.M., Nielsen, F.S., Thygesen, P., Reedtz-Runge, S., Kruse, T., Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem. 58 (2015), 7370–7380.
132. [132] Nauck, M.A., Petrie, J.R., Sesti, G., Mannucci, E., Courreges, J.P., Atkin, S., During, M., Jensen, C.B., Heller, S., The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA(1c) and body weight in patients with type 2 diabetes. Diabetologia, 55, 2012, S7.
133. [133] Roopenian, D.C., Akilesh, S., FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7 (2007), 715–725.
134. [134] Jimenez-Solem, E., Rasmussen, M.H., Christensen, M., Knop, F.K., Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr. Opin. Mol. Ther. 12 (2010), 790–797.
135. [135] Dungan, K.M., Povedano, S.T., Forst, T., Gonzalez, J.G., Atisso, C., Sealls, W., Fahrbach, J.L., Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 384 (2014), 1349–1357.
136. [136] Kuritzky, L., Umpierrez, G., Ekoe, J.M., Mancillas-Adame, L., Lando, L.F., Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad. Med. 126 (2014), 60–72.
137. [137] Sroda, K., Rydlewski, J., Langner, M., Kozubek, A., Grzybek, M., Sikorski, A.F., Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell. Mol. Biol. Lett. 10 (2005), 37–47.
138. [138] Schellenberger, V., Wang, C.W., Geething, N.C., Spink, B.J., Campbell, A., To, W., Scholle, M.D., Yin, Y., Yao, Y., Bogin, O., Cleland, J.L., Silverman, J., Stemmer, W.P., A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 27 (2009), 1186–1190.
139. [139] Chilkoti, A., Christensen, T., MacKay, J.A., Stimulus responsive elastin biopolymers: applications in medicine and biotechnology. Curr. Opin. Chem. Biol. 10 (2006), 652–657.
140. [140] Christiansen, M., Matson, M., Brazg, R., Georgopoulos, L., Arnold, S., Kramer, W., Shi, L., Strange, P., Weekly Subcutaneous Doses of PB1023 a Novel GLP-1 Analogue Reduce Glucose Exposure Dose Dependently. in, 2014, PhaseBio Pharmaceuticals.
141. [141] Pharmaceuticals, P.B., PhaseBio Initiated Phase 1 Study of Investigational Once-Weekly Basal Insulin for Potential Treatment of Diabetes. in, 2013.
142. [142] Wysham, C.H., MacConell, L.A., Maggs, D.G., Zhou, M., Griffin, P.S., Trautmann, M.E., Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. Mayo Clin. Proc. 90 (2015), 356–365.
143. [143] Ginsberg, B.H., Mixing pens and the future of diabetes drugs. J. Diabetes Sci. Technol., 2015.
144. [144] Amiram, M., Luginbuhl, K.M., Li, X., Feinglos, M.N., Chilkoti, A., Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 2792–2797.
145. [145] Amiram, M., Luginbuhl, K.M., Li, X., Feinglos, M.N., Chilkoti, A., A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection. J. Control. Release 172 (2013), 144–151.
146. [146] Henry, R.R., Rosenstock, J., Logan, D., Alessi, T., Luskey, K., Baron, M.A., Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J. Diabetes Complicat. 28 (2014), 393–398.
147. [147] Therapeutics, I., Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes. FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results, 2014.
148. [148] Leonard, T.W., Lynch, J., McKenna, M.J., Brayden, D.J., Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin. Drug Deliv. 3 (2006), 685–692.
149. [149] Chae, S.Y., Jin, C.H., Shin, H.J., Youn, Y.S., Lee, S., Lee, K.C., Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjug. Chem. 19 (2008), 334–341.
150. [150] Clardy-James, S., Chepurny, O.G., Leech, C.A., Holz, G.G., Doyle, R.P., Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagon-like peptide-1. ChemMedChem 8 (2013), 582–586.
151. [151] Eldor, R., Kidron, M., Greenberg-Shushlav, Y., Arbit, E., Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models. J. Diabetes Sci. Technol. 4 (2010), 1516–1523.
152. [152] Marino, M.T., Costello, D., Baughman, R., Boss, A., Cassidy, J., Damico, C., van Marle, S., van Vliet, A., Richardson, P.C., Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clin. Pharmacol. Ther. 88 (2010), 243–250.
153. [153] Rhinehart, A.S., Adding GLP-1 receptor agonist therapy to basal insulin for postprandial glucose control. Clin. Diabetes 33 (2015), 73–75.
154. [154] Young, L.A., Buse, J.B., GLP-1 receptor agonists and basal insulin in type 2 diabetes. Lancet 384 (2014), 2180–2181.
155. [155] Eng, C., Kramer, C.K., Zinman, B., Retnakaran, R., Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 384 (2014), 2228–2234.
156. [156] Rosenstock, J., Diamant, M., Silvestre, L., Souhami, E., Zhou, T., Fonseca, V., Benefits of a fixed-ratio formulation of once-daily insulin glargine/lixisenatide (LixiLan) vs glargine in type 2 diabetes inadequately controlled on metformin. Diabetologia, 57, 2014, S108.
157. [157] Gough, S.C.L., Bode, B., Woo, V., Rodbard, H.W., Linjawi, S., Poulsen, P., Damgaard, L.H., Buse, J.B., Invest, N.-D.-I.T., Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2 (2014), 885–893.
158. [158] Abu Hassan, H., Tohid, H., Mohd Amin, R., Long Bidin, M.B., Muthupalaniappen, L., Omar, K., Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. BMC Fam. Pract., 14, 2013, 164.
159. [159] Araujo, F., Fonte, P., Santos, H.A., Sarmento, B., Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control?. J. Diabetes Sci. Technol. 6 (2012), 1486–1497.
160. [160] Malkov, D., Angelo, R., Wang, H.Z., Flanders, E., Tang, H., Gomez-Orellana, I., Oral delivery of insulin with the eligen technology: mechanistic studies. Curr. Drug Deliv. 2 (2005), 191–197.
161. [161] Mullard, A., Oral GLP1 analogue rounds Phase II corner. Nat. Rev. Drug Discov., 14, 2015, 227.